Diagnosis and management of Silver–Russell syndrome: first international consensus statement
Year: 2016
Type: review
Abstract: This Consensus Statement summarizes recommendations for clinical diagnosis, investigation and management of patients with Silver-Russell syndrome (SRS), an imprinting disorder that causes prenatal and postnatal growth retardation. Considerable overlap exists between the care of individuals born small for gestational age and those with SRS. However, many specific management issues exist and evidence from controlled trials remains limited. SRS is primarily a clinical diagnosis; however, molecular testing enables confirmation of the clinical diagnosis and defines the subtype. A 'normal' result from a molecular test does not exclude the diagnosis of SRS. The management of children with SRS requires an experienced, multidisciplinary approach. Specific issues include growth failure, severe feeding difficulties, gastrointestinal problems, hypoglycaemia, body asymmetry, scoliosis, motor and speech delay and psychosocial challenges. An early emphasis on adequate nutritional status is important, with awareness that rapid postnatal weight gain might lead to subsequent increased risk of metabolic disorders. The benefits of treating patients with SRS with growth hormone include improved body composition, motor development and appetite, reduced risk of hypoglycaemia and increased height. Clinicians should be aware of possible premature adrenarche, fairly early and rapid central puberty and insulin resistance. Treatment with gonadotropin-releasing hormone analogues can delay progression of central puberty and preserve adult height potential. Long-term follow up is essential to determine the natural history and optimal management in adulthood.
Source: Nature Reviews Endocrinology
Authors: Emma L. Wakeling, Frédéric Brioude, Oluwakemi Lokulo-Sodipe, Susan M. O'Connell, Jennifer Salem, Jet Bliek, Ana P. M. Canton, Krystyna H. Chrzanowska, Justin H. Davies, Renuka P. Dias, Béatrice Dubern, Miriam Elbracht, Eloise Giabicani, Adda Grimberg, Karen Grønskov, Anita C. S. Hokken-Koelega, Alexander A. Jorge, Masayo Kagami, Agnes Linglart, Mohamad Maghnie, Klaus Mohnike, David Monk, Gudrun E. Moore, Philip G. Murray, Tsutomu Ogata, Isabelle Oliver Petit, Silvia Russo, Edith Said, Meropi Toumba, Zeynep Tümer, Gerhard Binder, Thomas Eggermann, Madeleine D. Harbison, I. Karen Temple, Deborah J. G. Mackay, Irène Netchine
Institutions: London North West Healthcare NHS Trust, Inserm, Hôpital Armand-Trousseau, Assistance Publique – Hôpitaux de Paris, Centre de Recherche Saint-Antoine, Université Pierre-et-Marie-Curie, Princess Anne Hospital, University Hospital Southampton NHS Foundation Trust, University of Southampton, Cork University Hospital, Amsterdam UMC Location University of Amsterdam, Universidade de São Paulo, Children's Memorial Health Institute, Birmingham Children's Hospital, University of Birmingham, RWTH Aachen University, Children's Hospital of Philadelphia, University of Pennsylvania, Copenhagen University Hospital, Rigshospitalet, Kennedy Center, Erasmus MC, National Research Institute for Child Health and Development, Bicêtre Hospital, Istituto Giannina Gaslini, University of Genoa, Otto-von-Guericke-Universität Magdeburg, Institut d'Investigació Biomédica de Bellvitge, Duran i Reynals Hospital, University College London, Royal Manchester Children's Hospital, Hamamatsu University, Hamamatsu University School of Medicine, Hôpital des Enfants, IRCCS Istituto Auxologico Italiano, University of Malta, Mater Dei Hospital, Paphos General Hospital, Cyprus Institute of Neurology and Genetics, University Children's Hospital Tübingen, Icahn School of Medicine at Mount Sinai
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: hybrid
Awards: Identifying factors required for genomic DNA methylation using the imprinting control protein ZFP57, Identification of the germline-derived GNAS gain-of-function mutations and clarification of the novel mechanism leading to GNAS loss-of-function, G6509482008, Is Growth Hormone treatment a long term benefit for patients with Silver Russell syndrome?
OpenAlex ID: W2507689999
